Investing in game-changers from early-stage and beyond.
17/06/2026
Where is biotech heading - and what does that mean for founders building in it today?
Shahar Tzafrir joined leading life sciences investors at Biomed 2026 last week - covering everything from what gets a company funded to the myths Israeli founders still believe, and where the sector is heading as AI reshapes the economics of drug and device development.
Full coverage in גלובס - Globes (Hebrew):
16/06/2026
Mars Security is out of stealth - and we couldn't be more excited to share this.✨
Most security teams aren't reactive by choice. They're reactive because the infrastructure to turn threat intelligence into actual coverage doesn't exist. Intelligence sits in reports. Detections are written by hand. Attackers move on before the gap closes.
Mars connects to the stack you already have and continuously converts threat intelligence into targeted hunts and production-ready detections - running across your environment without touching a single log.
Shahaf Galili, Matan Caspi, and Ran Lerer spent their careers on the attacker side. They didn't study how adversaries move through enterprise environments. They built the attacks.
50+ years of combined offensive experience. Now hunting the campaigns they once built.
Welcome to the light, Mars.
11/06/2026
Looking forward to EBN and Nextage's annual Hi-Tech Conference on June 24.
Yonatan Mandelbaum will be joining fellow investors, founders, and ecosystem leaders for a discussion on the state of Israel's tech ecosystem, fundraising trends, startup valuations, and the market forces shaping investment decisions in 2026.
Join us for a morning of insights, discussion, and networking.
Register here: https://eu1.hubs.ly/H0w495K0
27/05/2026
We met Noam Friedman, Rotem Abeles, and Amos Lahav in 2023, long before the defense tech wave, right when the world made it impossible to ignore what was coming. Today, Airis Labs emerges from stealth with $60M in total funding 🎉
Every conflict today is also a media event — a flood of visual data arriving faster than any team can process it. Airis turns that flood into structured intelligence that analysts and AI agents can act on in real time.
Founded by Israeli Special Operations veterans and ex-Palantir, the team understood this problem from the inside. They moved with unusual speed from founding to real-world deployment, built under pressure in operational environments, and turned that urgency into a platform government customers worldwide already rely on.
Congratulations to the entire Airis team on this exciting milestone! We're incredibly proud to have been your partners from the very beginning.
25/05/2026
Relocation is a strategic decision, not just an HR one.
Adi Yarel Toledano joined TheMarker and Discount Tech D-Academy panel this week to discuss the financial and tax complexities of employee relocation.
One key takeaway: companies are going global earlier than ever, and the right time to sort out tax and IP implications is *before* they become a problem at exit.
Great conversation alongside Odelia Lazimi (Meitar) and Asaf Miodovnik (Altshare), moderated by Omri Zerachovitz (TheMarker).
Full article: https://eu1.hubs.ly/H0vBPtR0
19/05/2026
Huge day for the Unframe team 🎉
$100M in TCV. 12 months. 400% NRR. One of the fastest-scaling enterprise AI companies - and a $50M round led by Highland Europe, bringing total funding to $100M.
Most enterprise AI initiatives still stall between pilot and production. Shay Levi, Larissa Schneider, and Adi Azarya built Unframe to close exactly that gap - turning real enterprise AI use cases into production-grade AI solutions in days, not quarters.
We're proud to have been part of the journey since the very beginning and excited to continue supporting their mission to reinvent software through the power of AI.
Congratulations to the entire Unframe team!
Rethinking how startups are built today: Rona Segev and Zohar Einy, Co-founder & CEO of Port, joined The Ecosystem podcast for an open conversation on what it takes to build and scale in a shifting landscape.
They looked back at the time Zohar was part of the TLV Partners team, and unpacked the founder–investor relationship - what makes it work, what breaks it, and what every CEO should keep in mind when managing their board.
They also discussed:
- The shift from AI Assistant to AI-Led engineering organizations
- Port’s early pivot toward agentic AI
- Lessons from selling to developers
- The reality behind the idea of one-person startups as AI reshapes how companies are built
🎧 In Hebrew. Listen on Spotify: https://eu1.hubs.ly/H0vnHQ20
04/05/2026
Our portfolio companies are on the lookout for exceptional talent.
From AI and engineering to product, sales and marketing, finance and HR, customer success and more, work alongside brilliant founders and some of the strongest teams in the industry.
Explore open roles:
https://eu1.hubs.ly/H0v0q3m0
29/04/2026
👏Big moment for Aidoc as they announce a $150M Series E, bringing their total funding to over $500M!
We’ve been lucky to be part of the journey early on, watching the team turn a bold vision into a clinical AI platform helping physicians make earlier and safer diagnoses by turning raw patient signals into actionable insights.
Powered by its CARE™ foundation model and enterprise AI platform, Aidoc aiOS™, the company is now deployed across nearly 2,000 hospitals, analyzing tens of millions of patient cases each year, and recently achieved a landmark FDA clearance for a multi-condition foundation model-based triage system.
Proud to be early partners to Elad, Michael, Guy and the team, and to support them as they continue building one of the leading platforms in clinical AI.
Tune in to our new series, Behind the Investment - conversations with the founders we back, sharing the real story behind each investment, from the first meeting to the moment of conviction, and what it takes to build enduring companies in the age of AI.
In this episode, Shahar Tzafrir sits down with Dov Gertz, Co-founder and CEO of Converge Bio, recently named to CTech’s 50 Most Promising Startups for 2026.
They talk about what’s actually behind that momentum - from discovering novel CRISPR systems using machine learning to building a generative lab for drug discovery, and the shift from models to full systems in AI-driven biology.
We're proud to be early partners to Dov, Oded Kalev, and Iddo Weiner, and to see the Converge team pushing this space forward.
🎧Listen on Spotify: https://eu1.hubs.ly/H0tS2yf0